Firms
Theme

COLM

Columbia Sportswear Co · NASDAQ

News

8 latest

Zacks Investment Research

Can Columbia Sportswear's Footwear Momentum Sustain Sales Growth?

Columbia Sportswear (COLM) is experiencing strong footwear growth with Q2 2026 sales up 5% to $117 million, driven by demand for technical products and premium styles like the sold-out Tellurix Titanium OutDry. Footwear is expected to outpace apparel growth in 2026, with Spring 2027 wholesale orders signaling continued momentum. The stock trades at a modest valuation discount but has underperformed the broader market in recent months.

Mentions COLM

Zacks Investment Research

GIL's Raised 2026 Outlook Puts Synergies and Tariff Refunds in Focus

Gildan Activewear raised its 2026 adjusted EPS guidance to $4.65-$4.75 and free cash flow outlook to $1 billion, driven by faster-than-expected HanesBrands integration synergies ($100 million) and $220 million in tariff refunds. However, soft retail demand and $4.7 billion in net debt remain headwinds. The company targets a 21.8% operating margin for 2026.

Zacks Investment Research

GIL Falls 11.1% in One Month as Retail Risks Test the Recovery Case

Gildan Activewear (GIL) shares declined 11.1% in four weeks as weak retail demand and HanesBrands integration execution risks weigh on investor sentiment. Despite raising 2026 adjusted EPS guidance to $4.65-$4.75 and operating margin forecast to 21.8%, the company's $4.7 billion net debt and 3.2X leverage remain concerns. The stock trades at a discount valuation but faces headwinds from retail softness and elevated acquisition-related costs.

Zacks Investment Research

Strength Seen in V.F. (VFC): Can Its 5.3% Jump Turn into More Strength?

V.F. Corporation's stock surged 5.3% to $15.79, driven by improving business fundamentals and successful transformation initiatives. The company benefits from strong performance in its Outdoor segment (The North Face, Timberland) and improved direct-to-consumer sales.

Zacks Investment Research

Can Somnigroup's Brand Strength and Innovation Efforts Drive Growth?

Somnigroup International Inc. (SGI) maintains a strong position in the global mattress and bedding industry through its portfolio of premium brands including Tempur-Pedic, Sealy, and Stearns & Foster. The company focuses on product innovation, operational efficiency, and diversified distribution channels.

Zacks Investment Research

NIKE's Shares Fall More Than 2% Post Q1 Earnings: What's Ahead?

NIKE shares declined 2.2% after reporting Q1 fiscal 2027 earnings that beat expectations but showed a 4% revenue decline. Greater China sales plunged 22% and weakness in Sportswear and Jordan Brand offset gains in performance categories. The company expects fiscal 2027 revenues to fall at a high-single-digit rate despite $2.5B in planned Pace savings, with analysts downgrading earnings estimates significantly.

Zacks Investment Research

NIKE Q1 Earnings Beat on Margin Gain, Stock Falls on Revenue Miss

NIKE beat EPS estimates at 48 cents but reported a 4.3% revenue decline to $11.2 billion, missing consensus. The company faces weakness in Sportswear, Jordan Brand, and Greater China, with Direct channel revenues down 8%. Management projects high-single-digit fiscal 2027 revenue declines and introduced the Pace restructuring program targeting $2.5 billion in savings through 2031.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $COLM · 0 threads

Sign in to post on $COLM

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev